{"ticker": {"uuid": "a6ab708f-0025-43c2-a164-bafa4475e8c2", "symbol": "EVAX", "name": "Evaxion Biotech AS", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "[6-K] Evaxion A/S Current Report (Foreign Issuer) | EVAX SEC Filing - Form 6-K", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPTEN0c2hnUWRaWDd4MmZEZGpBLUk3dnRnUl9BNi1jR0ppc0s3NGJ1dzFWcHA3VGZrUkhPcmg3WmdkR25zSHVfSU9oQmhfWWJRYkk4M01mYWxBamh3eXgtQkE3QzdHblctY01GVXc0a254WjFUeHk4d2pvdTFnMGJWVlVWdHdldWExM3dQWmFfOTJDMHhrQ1RCSUU2VGwwbXAyYlRHelJpMkN4NVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T11:31:31+00:00", "published_display": "17 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-present-three-clinical-efficacy-111500633.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T11:15:00+00:00", "published_display": "17 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion's personalized cancer vaccine showed a 75% response rate in melanoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaUxlSGdTVktBNjdnUGlDN3BST19Rdm9lSGcxUVExWThnTi1IeUZCNC0wSUlxNTkybGowZ1A3akY2RzJDa0xaZXZheDlsNEl2YjRVV1JCSkNuOFQtRlVKcnJ5bktsTnllbGJYXzhrUnlFWXF2RWpWa2pMWGZQWTYybmNJMF93SWY5dXNaTHdVTFNUZDJPQy1zVE56eGtQTG5xTldkcG00NFU2RzBnWDJ5TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T11:15:00+00:00", "published_display": "17 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Evaxion A/S \u2013 NASDAQ:EVAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZDB2MjJKVnBXMHZSd29meU9PSVhNb1oyNFlVbUdYWktNOEE1V2M3c1Z4Q3VBNjcxNFpMYVp4ZjF3ZlFLT1ZBai16bk05S09VSE41MFlUczlPVjNsN3NnNzlZWlFJOWVDY0ptZG5KdUd6SzczaUtoWVVXYTNFcEJ1aDI3VDZNX0M3N2Y4cG1Ia3hUY0xCc0wtRl9QajFwMjRybWlOanM4WHRFZFE?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T20:43:16+00:00", "published_display": "13 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evaxion (EVAX) Dips 1.25% as Stock Tests Support Near $3.01 - Butterfly Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQNW1BS3hrQy1YMmwtTkE3SVlpVng1U3lueDk3UmlFU0Y5bjVaTDA5WllCbWJRRlIwejR0UlRmZ194MkVxLWRJMW84LVM4S0ZwT3ZzY2dTQjRyMnFXb1Q5SDU2QjhmZHZPOU5XQUZNd3lSc1NiUzJwRng1RFVfMm91dXhxazkyOUFZb0twT2NIblpPVzN1TU9IMkplX2VFTlE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T20:35:02+00:00", "published_display": "12 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Evaxion A/S \u2013 NASDAQ:EVAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcTM1TERMR3ZqNndJaWRFcWx1SDB3ZmtMRXR1YVpPU29hYjNER21TcEJ6YTgteUhmWDVXMFZfRWRQTXVLcFprUmxGdkNQeHNMYXF6Nm9WUG1URlRnUEpGX2pLX0VaeVBtTU9MbWpSankyajBuVDBFQThudGNkTnlnNnBwaFEzUXlUT1hMcE9oaUUxOWdCcUFibG40bHBrbUIwclE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T17:51:54+00:00", "published_display": "12 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-presents-preclinical-data-cytomegalovirus-133000164.html", "source_name": "GlobeNewswire", "published_at": "2026-07-12T13:30:00+00:00", "published_display": "12 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present cytomegalovirus vaccine data at workshop", "summary": "Evaxion A/S (NASDAQ:EVAX) will present preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. This data, which includes antigens effective in cellular and animal models, is intended to guide antigen sele", "url": "https://m.uk.investing.com/news/stock-market-news/evaxion-to-present-cytomegalovirus-vaccine-data-at-workshop-93CH-4752720?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-06T15:41:49", "published_display": "06 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Rallies on Pipeline Progress - Financial Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTERveUl4UHFXTS12eTRHS0FBNFpLd2VuVmM2UHh5UmxBNDFvMlhqWGVXUHkzV3NUR21iVDdUdkFCTlU4TWRUcTNHZDNZM1ZVc28tMnBjUjF6eXRremh4ZFNPV3pOSGpBOUU3UTRNeURBQ2dDZURpSUE5Q3l4SnVhRW0xcE8zVHdYZ3pmU1dmeGdSaHZxZGJ0N2pRQ2xSeGdFRjh3R0ctRHlIeUQxNnExR0FGYndsRjhFbjNwS01RZkJ5LU1Pc3Z1SHlPT1pKajVsTy1GUzREbk5kNk0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-present-preclinical-data-cytomegalovirus-120000990.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T12:00:00+00:00", "published_display": "01 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion\u2019s CMV vaccine candidate gets new preclinical data in Montreal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWml2TXBIcUlOTmktYndpWVVBMzVZMWFfdjZ5TFhfY1RIMktKelI5SVAzcFlsUVZnbDQ0T1NFUDJEeVBRcDI1aUZjOGJfR2p2MDlVWXZaMjJkeTJNRUQ3R3hhZVktbzIxWlo3eGdQX0pPeUdLb2UyZF80Q1FTUnNPc1RmV2hwYXcxTDM3a0FiVGFrQXVNQW1MUWlnd3lXXzE0VGZ5cVJ3TGpvTklxWXJ0SDNsd3NIUGh3ZnBucDBTNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target forecast for Evaxion A/S (EVAX) for the year 2027, based on analysis from 4 financial analysts. It includes sections for price target, analyst ratings, and EPS and revenue actuals and estimates, highlighting that the information is not investm", "url": "https://www.tradingview.com/symbols/NASDAQ-EVAX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:31", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion (EVAX) Slides 2.4% as Shares Test Key Support Levels - EMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSzdvQ0NzZkppUGNZTnVyS1RKcExPT0JFS0hhT3NTaDNMaGFrMnBheWNwVUEwNDItaGpINnpVeUEzMkI2R3E5YklkR3NyZE8taDFaNG9USGRWYVlnRW5KZ05DQzYwaHNEZS0xem90MnlrckJjTTlHbndXTFpIM1BlM2V1anpnbmZTbW5yM0tLaldoMnhOR3dDN0FGcWZkdU5p?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T17:31:27+00:00", "published_display": "25 Jun 2026 17:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Evaxion Biotech A/S (EVAX), noting that no specific risk assessment score is currently available, but the biotechnology industry average is 3.36. Key metrics such as the stock's beta (0.26), indicating underperformance in rising markets", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T02:41:24", "published_display": "23 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Evaxion Biotech A/S (EVAX), highlighting its current price momentum score of 3.95 and positioning the stock between resistance at $3.85 and support at $2.65 for range-bound swing trading. It details various technical indicators like M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:40:43", "published_display": "18 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evaxion Biotech A/S (EVAX) has an earnings forecast score of 8.00, ranking 165 out of 389 in its industry. Analysts have set an average price target of $11.00, with a consensus \"Buy\" rating based on 4 analysts. The company's stock closed at $3.050, showing an 8.13% decrease on Ju", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:28", "published_display": "18 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey is a placeholder for Evaxion Biotech A/S (EVAX) revenue breakdown information. It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:40", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Evaxion Biotech A/S (EVAX) dividends and stock splits. It notes that the company has not distributed any dividends in the past five years. However, it lists several stock merger events with varying ratios in late 2024 and early 2024.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evaxion Biotech A/S (EVAX), listing major shareholders such as Merck & Co Inc and Merck Sharp & Dohme Corporation, along with their respective proportions. It also presents institutional shareholding data from Q1 2023 to Q1 2026, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Institutional Confidence", "summary": "Evaxion Biotech A/S (EVAX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.88%, a 48.82% increase quarter-over-quarter. James Simons is the largest", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:28", "published_display": "17 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Evaxion Biotech A/S (EVAX) currently holds a financial score of 7.14, ranking 148th out of 388 companies in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's financial overview sections, including Quality", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T17:41:10", "published_display": "17 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Evaxion Biotech A/S (EVAX), noting its current valuation score of 9.76, ranking 15th within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio is -15.96, which is significantly below its recent high and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:41:10", "published_display": "17 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-built AML vaccine from Evaxion makes immune cells kill cancer in lab tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSXEwRUU4dUdUOFYzUnFXdzFMUlFnbzVDUm5Wd0gtdG9hbmxIcnJDamFGbFZqekw4ZjhNbHJKUS02aXJVNEhmQjlMUDFhNVA0OE9oT3V2Q1N1bHJPUzFBT213bEt2M3locFJFRnM5ZExXazZGbVp5bFJkNlFhblhDdU0tbWkwbEQtcXJ3ajVmbFpQVllVa0pySkV1dTZUQVZ3TWhOd3JPb2lJRi1lRGNKcjNfTFBmYVpOV09Pdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX - Evaxion A/S ADR Stock Price and Quote", "summary": "This article provides comprehensive stock information for Evaxion A/S (EVAX), an ADR engaged in immunotherapy development. It details the company's latest stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases highlighting thei", "url": "https://finviz.com/stock?t=EVAX", "source_name": "Finviz", "published_at": "2026-06-03T12:11:37", "published_display": "03 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S EVAX", "summary": "This page provides an overview of Evaxion Biotech A/S (EVAX) stock performance, showing its current price of 4.080 USD, a slight increase of 0.49%. The company has a market capitalization of 34.03M and its stock information is delayed by 15 minutes. The page also includes section", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/comments", "source_name": "TradingKey", "published_at": "2026-05-17T19:10:07", "published_display": "17 May 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AI-picked cancer vaccine targets triggered immune response 86% of the time", "summary": "Evaxion (NASDAQ: EVAX) announced positive Phase 2 data for its personalized cancer vaccine, EVX-01, showing that its AI-Immunology\u2122 platform accurately identified vaccine targets that triggered tumor-specific immune responses in 86% of cases. The vaccine, tested in combination wi", "url": "https://www.stocktitan.net/news/EVAX/evaxion-s-ai-immunology-tm-platform-demonstrates-86-vaccine-target-w2g00grv26em.html", "source_name": "Stock Titan", "published_at": "2026-05-11T15:09:17", "published_display": "11 May 2026 15:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evaxion to post Q1 results before market open, webcast at 8:30 ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQUl1Si1vRkdfVW9ZTVNUcnoybzhGY1M1by1KYmZRMFZ0elo2akl1UzhCMUtBRUI1aDMxbG1rckl3NV9ObmxydFRKcGpKRzdneUY1Y2tCaUNJMWd3a29zSUpkcjRsRThOU3dHUHN0WFh0bnB2clB5R2s0Y3A0em5rNzVGX1QtOHBrXzliVWJUSUxZM1ItZnVveEYyUnkwSzhFeW1YdGNoeGNoa21XSjdtaEF1X09idnVfM3pYX2ppd24?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Elevates CSO Birgitte R\u00f8n\u00f8 to Dual CSO-COO Role to Drive AI Vaccine Strategy", "summary": "Evaxion Biotech has promoted its Chief Scientific Officer, Birgitte R\u00f8n\u00f8, to a dual role as CSO and COO, effective April 27, 2026. This strategic move aims to improve strategy execution and enhance the visibility of the company's AI-Immunology platform to partners and investors. ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX-Q/pressreleases/1559316/evaxion-elevates-cso-birgitte-rono-to-dual-cso-coo-role-to-drive-ai-vaccine-strategy/", "source_name": "The Globe and Mail", "published_at": "2026-04-28T14:09:27", "published_display": "28 Apr 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers", "summary": "Evaxion A/S shareholders approved an expanded capacity for equity and convertible financing at their Annual General Meeting on April 16, 2026. This decision provides the company with greater financial flexibility to incentivize personnel and secure funding, though it introduces p", "url": "https://www.tipranks.com/news/company-announcements/evaxion-a-s-wins-shareholder-approval-for-expanded-equity-and-convertible-financing-powers", "source_name": "TipRanks", "published_at": "2026-04-22T11:09:03", "published_display": "22 Apr 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Posts Strong Phase 2 Data as AI-Designed Cancer Vaccine Hits 86% Target Precision", "summary": "Evaxion Biotech announced strong Phase 2 data for its AI-designed cancer vaccine, EVX-01, showing 86% target precision in advanced melanoma patients and durable immunity. The vaccine, combined with Keytruda, achieved a 75% objective response rate in clinical trials. This reinforc", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX-Q/pressreleases/1385880/evaxion-posts-strong-phase-2-data-as-ai-designed-cancer-vaccine-hits-86-target-precision/", "source_name": "The Globe and Mail", "published_at": "2026-04-21T11:09:30", "published_display": "21 Apr 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations", "summary": "Evaxion Biotech (EVAX) has scheduled its 2026 Annual General Meeting for April 16, 2026, in H\u00f8rsholm, Denmark. Key agenda items include reviewing the 2025 financial report, re-electing directors, proposing a new board member, reappointing the auditor, and seeking authorization to", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/863454/evaxion-calls-april-16-2026-agm-to-expand-capital-and-warrant-authorizations/", "source_name": "The Globe and Mail", "published_at": "2026-03-24T09:11:04", "published_display": "24 Mar 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech's Earnings: A Preview", "summary": "Evaxion Biotech (NASDAQ: EVAX) is set to announce its quarterly earnings on March 5, 2026, with analysts estimating an EPS of $-0.19. Investors will be looking for the company to surpass estimates and provide positive guidance. The article notes that Evaxion Biotech's stock price", "url": "https://www.sahmcapital.com/news/content/evaxion-biotechs-earnings-a-preview-2026-03-04", "source_name": "Sahm", "published_at": "2026-03-08T23:51:48", "published_display": "08 Mar 2026 23:51", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Delays 2025 Annual Report Filing Due to Technical Issues", "summary": "Evaxion Biotech announced a brief technical delay in filing its 2025 annual report, clarifying that the issue was due to external vendors and not financial or operational problems. This delayed a scheduled conference call by one day. While analyst sentiment is a \"Buy\" with a $10.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/607419/evaxion-delays-2025-annual-report-filing-due-to-technical-issues/", "source_name": "The Globe and Mail", "published_at": "2026-03-06T08:06:00", "published_display": "06 Mar 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech Issues Over 9 Million New Warrants to Insiders in February 2026", "summary": "Evaxion Biotech (EVAX) has issued over 9 million new warrants to its insiders in February 2026, totaling 6.54 million on Feb 5 and another 2.5 million on Feb 16. These issuances, primarily to directors, management, and employees, are part of the company's equity-based incentive s", "url": "https://www.tipranks.com/news/company-announcements/evaxion-biotech-issues-over-9-million-new-warrants-to-insiders-in-february-2026", "source_name": "TipRanks", "published_at": "2026-02-27T22:51:19", "published_display": "27 Feb 2026 22:51", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Should I Buy", "summary": "An analysis of Evaxion A/S (EVAX) suggests it is not a strong buy for long-term beginner investors, recommending a \"hold\" position due to weak technical setup, lack of recent news catalysts, and mixed analyst sentiment. While analysts like Lake Street and JonesResearch maintain \"", "url": "https://intellectia.ai/en/stock/EVAX/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-17T22:09:14", "published_display": "17 Feb 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion A/S to Announce Q3 2025 Financial Results and Business Update", "summary": "Evaxion A/S will announce its financial results for the third quarter of 2025 and provide a business update. This announcement and update will inform stakeholders about the company's performance and strategic direction.", "url": "https://www.msn.com/en-us/money/companies/evaxion-as-to-announce-q3-2025-financial-results-and-business-update/ar-AA1PzUSa?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-01-22T15:30:24", "published_display": "22 Jan 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI vaccine developer Evaxion to share 2026 milestones in San Francisco", "summary": "Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, will present its 2026 company milestones and provide an update on January 13, 2026, at the Biotech Showcase conference in San Francisco. CEO Helen Tayton-Martin will lead the presentation, and the company plans to engage w", "url": "https://www.stocktitan.net/news/EVAX/evaxion-to-present-2026-company-milestones-at-biotech-showcase-ubl3x6memfgc.html", "source_name": "Stock Titan", "published_at": "2026-01-09T02:43:24", "published_display": "09 Jan 2026 02:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million", "summary": "Evaxion Biotech A/S has filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs) worth up to $45.5 million. This financial move, part of an existing sales agreement with JonesTrading Institutional Services LLC, aims to strengthen the ", "url": "https://www.tipranks.com/news/company-announcements/evaxion-biotech-announces-new-ads-offering-to-raise-45-5-million", "source_name": "TipRanks", "published_at": "2026-01-02T23:09:07", "published_display": "02 Jan 2026 23:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out", "summary": "Evaxion Biotech is looking for a new partner for its gonorrhea vaccine candidate, EVX-B2, after Merck & Co. decided not to exercise its option. Despite this, Evaxion retains global rights to EVX-B2 and states that Merck's decision does not impact its cash runway, which extends to", "url": "https://www.sahmcapital.com/news/content/evaxion-seeks-new-partner-for-gonorrhea-vaccine-after-merck-opts-out-2025-12-19", "source_name": "Sahm", "published_at": "2025-12-24T01:11:31", "published_display": "24 Dec 2025 01:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MSD declines option for Evaxion\u2019s gonorrhea vaccine candidate", "summary": "MSD (Merck & Co., Inc.) has decided not to exercise its option for Evaxion\u2019s gonorrhea vaccine candidate, EVX-B2, allowing Evaxion to seek a new licensing partner. This decision follows MSD's earlier exercise of an option for another Evaxion vaccine candidate, EVX-B3, which could", "url": "https://www.investing.com/news/company-news/msd-declines-option-for-evaxions-gonorrhea-vaccine-candidate-93CH-4417084", "source_name": "Investing.com", "published_at": "2025-12-19T07:05:00", "published_display": "19 Dec 2025 07:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to Outline 2026 Milestones at Biotech Showcase in San Francisco", "summary": "Evaxion Biotech (EVAX) announced it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco from January 12-14, 2026. CEO Helen Tayton-Martin is scheduled to speak, and the company plans to engage with potential ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/36947947/evaxion-to-outline-2026-milestones-at-biotech-showcase-in-san-francisco/", "source_name": "The Globe and Mail", "published_at": "2025-12-06T14:28:40", "published_display": "06 Dec 2025 14:28", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "[6-K] Evaxion A/S Current Report (Foreign Issuer) | EVAX SEC Filing - Form 6-K", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPTEN0c2hnUWRaWDd4MmZEZGpBLUk3dnRnUl9BNi1jR0ppc0s3NGJ1dzFWcHA3VGZrUkhPcmg3WmdkR25zSHVfSU9oQmhfWWJRYkk4M01mYWxBamh3eXgtQkE3QzdHblctY01GVXc0a254WjFUeHk4d2pvdTFnMGJWVlVWdHdldWExM3dQWmFfOTJDMHhrQ1RCSUU2VGwwbXAyYlRHelJpMkN4NVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T11:31:31+00:00", "published_display": "17 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-present-three-clinical-efficacy-111500633.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T11:15:00+00:00", "published_display": "17 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion's personalized cancer vaccine showed a 75% response rate in melanoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaUxlSGdTVktBNjdnUGlDN3BST19Rdm9lSGcxUVExWThnTi1IeUZCNC0wSUlxNTkybGowZ1A3akY2RzJDa0xaZXZheDlsNEl2YjRVV1JCSkNuOFQtRlVKcnJ5bktsTnllbGJYXzhrUnlFWXF2RWpWa2pMWGZQWTYybmNJMF93SWY5dXNaTHdVTFNUZDJPQy1zVE56eGtQTG5xTldkcG00NFU2RzBnWDJ5TA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T11:15:00+00:00", "published_display": "17 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Evaxion A/S \u2013 NASDAQ:EVAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZDB2MjJKVnBXMHZSd29meU9PSVhNb1oyNFlVbUdYWktNOEE1V2M3c1Z4Q3VBNjcxNFpMYVp4ZjF3ZlFLT1ZBai16bk05S09VSE41MFlUczlPVjNsN3NnNzlZWlFJOWVDY0ptZG5KdUd6SzczaUtoWVVXYTNFcEJ1aDI3VDZNX0M3N2Y4cG1Ia3hUY0xCc0wtRl9QajFwMjRybWlOanM4WHRFZFE?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T20:43:16+00:00", "published_display": "13 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion (EVAX) Dips 1.25% as Stock Tests Support Near $3.01 - Butterfly Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQNW1BS3hrQy1YMmwtTkE3SVlpVng1U3lueDk3UmlFU0Y5bjVaTDA5WllCbWJRRlIwejR0UlRmZ194MkVxLWRJMW84LVM4S0ZwT3ZzY2dTQjRyMnFXb1Q5SDU2QjhmZHZPOU5XQUZNd3lSc1NiUzJwRng1RFVfMm91dXhxazkyOUFZb0twT2NIblpPVzN1TU9IMkplX2VFTlE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T20:35:02+00:00", "published_display": "12 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Evaxion A/S \u2013 NASDAQ:EVAX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcTM1TERMR3ZqNndJaWRFcWx1SDB3ZmtMRXR1YVpPU29hYjNER21TcEJ6YTgteUhmWDVXMFZfRWRQTXVLcFprUmxGdkNQeHNMYXF6Nm9WUG1URlRnUEpGX2pLX0VaeVBtTU9MbWpSankyajBuVDBFQThudGNkTnlnNnBwaFEzUXlUT1hMcE9oaUUxOWdCcUFibG40bHBrbUIwclE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T17:51:54+00:00", "published_display": "12 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-presents-preclinical-data-cytomegalovirus-133000164.html", "source_name": "GlobeNewswire", "published_at": "2026-07-12T13:30:00+00:00", "published_display": "12 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present cytomegalovirus vaccine data at workshop", "summary": "Evaxion A/S (NASDAQ:EVAX) will present preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. This data, which includes antigens effective in cellular and animal models, is intended to guide antigen sele", "url": "https://m.uk.investing.com/news/stock-market-news/evaxion-to-present-cytomegalovirus-vaccine-data-at-workshop-93CH-4752720?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-06T15:41:49", "published_display": "06 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Rallies on Pipeline Progress - Financial Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTERveUl4UHFXTS12eTRHS0FBNFpLd2VuVmM2UHh5UmxBNDFvMlhqWGVXUHkzV3NUR21iVDdUdkFCTlU4TWRUcTNHZDNZM1ZVc28tMnBjUjF6eXRremh4ZFNPV3pOSGpBOUU3UTRNeURBQ2dDZURpSUE5Q3l4SnVhRW0xcE8zVHdYZ3pmU1dmeGdSaHZxZGJ0N2pRQ2xSeGdFRjh3R0ctRHlIeUQxNnExR0FGYndsRjhFbjNwS01RZkJ5LU1Pc3Z1SHlPT1pKajVsTy1GUzREbk5kNk0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-present-preclinical-data-cytomegalovirus-120000990.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T12:00:00+00:00", "published_display": "01 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion\u2019s CMV vaccine candidate gets new preclinical data in Montreal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWml2TXBIcUlOTmktYndpWVVBMzVZMWFfdjZ5TFhfY1RIMktKelI5SVAzcFlsUVZnbDQ0T1NFUDJEeVBRcDI1aUZjOGJfR2p2MDlVWXZaMjJkeTJNRUQ3R3hhZVktbzIxWlo3eGdQX0pPeUdLb2UyZF80Q1FTUnNPc1RmV2hwYXcxTDM3a0FiVGFrQXVNQW1MUWlnd3lXXzE0VGZ5cVJ3TGpvTklxWXJ0SDNsd3NIUGh3ZnBucDBTNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target forecast for Evaxion A/S (EVAX) for the year 2027, based on analysis from 4 financial analysts. It includes sections for price target, analyst ratings, and EPS and revenue actuals and estimates, highlighting that the information is not investm", "url": "https://www.tradingview.com/symbols/NASDAQ-EVAX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:31", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion (EVAX) Slides 2.4% as Shares Test Key Support Levels - EMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSzdvQ0NzZkppUGNZTnVyS1RKcExPT0JFS0hhT3NTaDNMaGFrMnBheWNwVUEwNDItaGpINnpVeUEzMkI2R3E5YklkR3NyZE8taDFaNG9USGRWYVlnRW5KZ05DQzYwaHNEZS0xem90MnlrckJjTTlHbndXTFpIM1BlM2V1anpnbmZTbW5yM0tLaldoMnhOR3dDN0FGcWZkdU5p?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T17:31:27+00:00", "published_display": "25 Jun 2026 17:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Evaxion Biotech A/S (EVAX), noting that no specific risk assessment score is currently available, but the biotechnology industry average is 3.36. Key metrics such as the stock's beta (0.26), indicating underperformance in rising markets", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T02:41:24", "published_display": "23 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Evaxion Biotech A/S (EVAX), highlighting its current price momentum score of 3.95 and positioning the stock between resistance at $3.85 and support at $2.65 for range-bound swing trading. It details various technical indicators like M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:40:43", "published_display": "18 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evaxion Biotech A/S (EVAX) has an earnings forecast score of 8.00, ranking 165 out of 389 in its industry. Analysts have set an average price target of $11.00, with a consensus \"Buy\" rating based on 4 analysts. The company's stock closed at $3.050, showing an 8.13% decrease on Ju", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:28", "published_display": "18 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey is a placeholder for Evaxion Biotech A/S (EVAX) revenue breakdown information. It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:40", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Evaxion Biotech A/S (EVAX) dividends and stock splits. It notes that the company has not distributed any dividends in the past five years. However, it lists several stock merger events with varying ratios in late 2024 and early 2024.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evaxion Biotech A/S (EVAX), listing major shareholders such as Merck & Co Inc and Merck Sharp & Dohme Corporation, along with their respective proportions. It also presents institutional shareholding data from Q1 2023 to Q1 2026, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:40", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Institutional Confidence", "summary": "Evaxion Biotech A/S (EVAX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.88%, a 48.82% increase quarter-over-quarter. James Simons is the largest", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:28", "published_display": "17 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Evaxion Biotech A/S (EVAX) currently holds a financial score of 7.14, ranking 148th out of 388 companies in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's financial overview sections, including Quality", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T17:41:10", "published_display": "17 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S (EVAX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Evaxion Biotech A/S (EVAX), noting its current valuation score of 9.76, ranking 15th within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio is -15.96, which is significantly below its recent high and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:41:10", "published_display": "17 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-built AML vaccine from Evaxion makes immune cells kill cancer in lab tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSXEwRUU4dUdUOFYzUnFXdzFMUlFnbzVDUm5Wd0gtdG9hbmxIcnJDamFGbFZqekw4ZjhNbHJKUS02aXJVNEhmQjlMUDFhNVA0OE9oT3V2Q1N1bHJPUzFBT213bEt2M3locFJFRnM5ZExXazZGbVp5bFJkNlFhblhDdU0tbWkwbEQtcXJ3ajVmbFpQVllVa0pySkV1dTZUQVZ3TWhOd3JPb2lJRi1lRGNKcjNfTFBmYVpOV09Pdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX - Evaxion A/S ADR Stock Price and Quote", "summary": "This article provides comprehensive stock information for Evaxion A/S (EVAX), an ADR engaged in immunotherapy development. It details the company's latest stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases highlighting thei", "url": "https://finviz.com/stock?t=EVAX", "source_name": "Finviz", "published_at": "2026-06-03T12:11:37", "published_display": "03 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech A/S EVAX", "summary": "This page provides an overview of Evaxion Biotech A/S (EVAX) stock performance, showing its current price of 4.080 USD, a slight increase of 0.49%. The company has a market capitalization of 34.03M and its stock information is delayed by 15 minutes. The page also includes section", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-evax/comments", "source_name": "TradingKey", "published_at": "2026-05-17T19:10:07", "published_display": "17 May 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-picked cancer vaccine targets triggered immune response 86% of the time", "summary": "Evaxion (NASDAQ: EVAX) announced positive Phase 2 data for its personalized cancer vaccine, EVX-01, showing that its AI-Immunology\u2122 platform accurately identified vaccine targets that triggered tumor-specific immune responses in 86% of cases. The vaccine, tested in combination wi", "url": "https://www.stocktitan.net/news/EVAX/evaxion-s-ai-immunology-tm-platform-demonstrates-86-vaccine-target-w2g00grv26em.html", "source_name": "Stock Titan", "published_at": "2026-05-11T15:09:17", "published_display": "11 May 2026 15:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to post Q1 results before market open, webcast at 8:30 ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQUl1Si1vRkdfVW9ZTVNUcnoybzhGY1M1by1KYmZRMFZ0elo2akl1UzhCMUtBRUI1aDMxbG1rckl3NV9ObmxydFRKcGpKRzdneUY1Y2tCaUNJMWd3a29zSUpkcjRsRThOU3dHUHN0WFh0bnB2clB5R2s0Y3A0em5rNzVGX1QtOHBrXzliVWJUSUxZM1ItZnVveEYyUnkwSzhFeW1YdGNoeGNoa21XSjdtaEF1X09idnVfM3pYX2ppd24?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Elevates CSO Birgitte R\u00f8n\u00f8 to Dual CSO-COO Role to Drive AI Vaccine Strategy", "summary": "Evaxion Biotech has promoted its Chief Scientific Officer, Birgitte R\u00f8n\u00f8, to a dual role as CSO and COO, effective April 27, 2026. This strategic move aims to improve strategy execution and enhance the visibility of the company's AI-Immunology platform to partners and investors. ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX-Q/pressreleases/1559316/evaxion-elevates-cso-birgitte-rono-to-dual-cso-coo-role-to-drive-ai-vaccine-strategy/", "source_name": "The Globe and Mail", "published_at": "2026-04-28T14:09:27", "published_display": "28 Apr 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers", "summary": "Evaxion A/S shareholders approved an expanded capacity for equity and convertible financing at their Annual General Meeting on April 16, 2026. This decision provides the company with greater financial flexibility to incentivize personnel and secure funding, though it introduces p", "url": "https://www.tipranks.com/news/company-announcements/evaxion-a-s-wins-shareholder-approval-for-expanded-equity-and-convertible-financing-powers", "source_name": "TipRanks", "published_at": "2026-04-22T11:09:03", "published_display": "22 Apr 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Posts Strong Phase 2 Data as AI-Designed Cancer Vaccine Hits 86% Target Precision", "summary": "Evaxion Biotech announced strong Phase 2 data for its AI-designed cancer vaccine, EVX-01, showing 86% target precision in advanced melanoma patients and durable immunity. The vaccine, combined with Keytruda, achieved a 75% objective response rate in clinical trials. This reinforc", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX-Q/pressreleases/1385880/evaxion-posts-strong-phase-2-data-as-ai-designed-cancer-vaccine-hits-86-target-precision/", "source_name": "The Globe and Mail", "published_at": "2026-04-21T11:09:30", "published_display": "21 Apr 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations", "summary": "Evaxion Biotech (EVAX) has scheduled its 2026 Annual General Meeting for April 16, 2026, in H\u00f8rsholm, Denmark. Key agenda items include reviewing the 2025 financial report, re-electing directors, proposing a new board member, reappointing the auditor, and seeking authorization to", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/863454/evaxion-calls-april-16-2026-agm-to-expand-capital-and-warrant-authorizations/", "source_name": "The Globe and Mail", "published_at": "2026-03-24T09:11:04", "published_display": "24 Mar 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech's Earnings: A Preview", "summary": "Evaxion Biotech (NASDAQ: EVAX) is set to announce its quarterly earnings on March 5, 2026, with analysts estimating an EPS of $-0.19. Investors will be looking for the company to surpass estimates and provide positive guidance. The article notes that Evaxion Biotech's stock price", "url": "https://www.sahmcapital.com/news/content/evaxion-biotechs-earnings-a-preview-2026-03-04", "source_name": "Sahm", "published_at": "2026-03-08T23:51:48", "published_display": "08 Mar 2026 23:51", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Delays 2025 Annual Report Filing Due to Technical Issues", "summary": "Evaxion Biotech announced a brief technical delay in filing its 2025 annual report, clarifying that the issue was due to external vendors and not financial or operational problems. This delayed a scheduled conference call by one day. While analyst sentiment is a \"Buy\" with a $10.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/607419/evaxion-delays-2025-annual-report-filing-due-to-technical-issues/", "source_name": "The Globe and Mail", "published_at": "2026-03-06T08:06:00", "published_display": "06 Mar 2026 08:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech Issues Over 9 Million New Warrants to Insiders in February 2026", "summary": "Evaxion Biotech (EVAX) has issued over 9 million new warrants to its insiders in February 2026, totaling 6.54 million on Feb 5 and another 2.5 million on Feb 16. These issuances, primarily to directors, management, and employees, are part of the company's equity-based incentive s", "url": "https://www.tipranks.com/news/company-announcements/evaxion-biotech-issues-over-9-million-new-warrants-to-insiders-in-february-2026", "source_name": "TipRanks", "published_at": "2026-02-27T22:51:19", "published_display": "27 Feb 2026 22:51", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVAX Should I Buy", "summary": "An analysis of Evaxion A/S (EVAX) suggests it is not a strong buy for long-term beginner investors, recommending a \"hold\" position due to weak technical setup, lack of recent news catalysts, and mixed analyst sentiment. While analysts like Lake Street and JonesResearch maintain \"", "url": "https://intellectia.ai/en/stock/EVAX/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-17T22:09:14", "published_display": "17 Feb 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion A/S to Announce Q3 2025 Financial Results and Business Update", "summary": "Evaxion A/S will announce its financial results for the third quarter of 2025 and provide a business update. This announcement and update will inform stakeholders about the company's performance and strategic direction.", "url": "https://www.msn.com/en-us/money/companies/evaxion-as-to-announce-q3-2025-financial-results-and-business-update/ar-AA1PzUSa?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-01-22T15:30:24", "published_display": "22 Jan 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI vaccine developer Evaxion to share 2026 milestones in San Francisco", "summary": "Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, will present its 2026 company milestones and provide an update on January 13, 2026, at the Biotech Showcase conference in San Francisco. CEO Helen Tayton-Martin will lead the presentation, and the company plans to engage w", "url": "https://www.stocktitan.net/news/EVAX/evaxion-to-present-2026-company-milestones-at-biotech-showcase-ubl3x6memfgc.html", "source_name": "Stock Titan", "published_at": "2026-01-09T02:43:24", "published_display": "09 Jan 2026 02:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million", "summary": "Evaxion Biotech A/S has filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs) worth up to $45.5 million. This financial move, part of an existing sales agreement with JonesTrading Institutional Services LLC, aims to strengthen the ", "url": "https://www.tipranks.com/news/company-announcements/evaxion-biotech-announces-new-ads-offering-to-raise-45-5-million", "source_name": "TipRanks", "published_at": "2026-01-02T23:09:07", "published_display": "02 Jan 2026 23:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out", "summary": "Evaxion Biotech is looking for a new partner for its gonorrhea vaccine candidate, EVX-B2, after Merck & Co. decided not to exercise its option. Despite this, Evaxion retains global rights to EVX-B2 and states that Merck's decision does not impact its cash runway, which extends to", "url": "https://www.sahmcapital.com/news/content/evaxion-seeks-new-partner-for-gonorrhea-vaccine-after-merck-opts-out-2025-12-19", "source_name": "Sahm", "published_at": "2025-12-24T01:11:31", "published_display": "24 Dec 2025 01:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MSD declines option for Evaxion\u2019s gonorrhea vaccine candidate", "summary": "MSD (Merck & Co., Inc.) has decided not to exercise its option for Evaxion\u2019s gonorrhea vaccine candidate, EVX-B2, allowing Evaxion to seek a new licensing partner. This decision follows MSD's earlier exercise of an option for another Evaxion vaccine candidate, EVX-B3, which could", "url": "https://www.investing.com/news/company-news/msd-declines-option-for-evaxions-gonorrhea-vaccine-candidate-93CH-4417084", "source_name": "Investing.com", "published_at": "2025-12-19T07:05:00", "published_display": "19 Dec 2025 07:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaxion to Outline 2026 Milestones at Biotech Showcase in San Francisco", "summary": "Evaxion Biotech (EVAX) announced it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco from January 12-14, 2026. CEO Helen Tayton-Martin is scheduled to speak, and the company plans to engage with potential ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/36947947/evaxion-to-outline-2026-milestones-at-biotech-showcase-in-san-francisco/", "source_name": "The Globe and Mail", "published_at": "2025-12-06T14:28:40", "published_display": "06 Dec 2025 14:28", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 51, "sentiment_summary": {"positive": 8, "negative": 9, "neutral": 34, "score": 51, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 3.17, "latest_week": "2026-07-10", "one_week_move": -7.0, "four_week_move": -12.9, "twelve_week_move": -28.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.830309, "market_dynamics_buy_signal": false, "relative_strength": -33.836166, "fair_value_gap": -77.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.188, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.0% over one week, -12.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "The Globe and Mail", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "dars.gov.et", "count": 3}, {"label": "TipRanks", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.0% over one week, -12.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "[6-K] Evaxion A/S Current Report (Foreign Issuer) | EVAX SEC Filing - Form 6-K"}], "updated_at": "2026-07-17T15:29:08.228731+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}